Navigating Post-Platinum Treatment Pathways for Metastatic NSCLC
This thought-provoking debate features leading experts in thoracic oncology as they critically examine emerging strategies and ongoing challenges in the management of metastatic non–small cell lung cancer (NSCLC). Topics include the integration of novel modalities such as tumor treating fields (TTFs), when to use immunotherapy as second-line treatment, and the addition of radiation therapy to treatment plans. Designed for oncology professionals, this discussion delivers valuable insights into the evolving standards of care and innovative approaches that may shape the next era of NSCLC treatment.
Round 1
Immunotherapy vs Alternative Therapy
The debate opens with an insightful review of existing treatment paradigms for metastatic NSCLC. In patient scenarios where pre-existing conditions previously hindered immunotherapy use, panelists discuss which treatment should be used as second-line therapy.
Round 2
Adding Radiation Therapy vs Switching Treatments
This round delves into the role of radiation therapy. Panelists weigh the relevance of traditional chemotherapy agents against the use of radiation therapy. The discussion explores patient selection, long-term toxicity, and whether certain populations may benefit from radiation-based regimens in an era of biologically driven care.
Round 3
For TTFields vs Against TTFields
The third round tackles one of the most novel and debated modalities: Tumor Treating Fields (TTFs). The panel evaluates the clinical evidence, mechanistic rationale, and practical considerations behind integrating TTFs into metastatic NSCLC management. Panelists highlight promising survival data and the potential for synergy with existing treatments, along with logistical considerations for patients.
This is a non-CME activity. The views and opinions expressed by the presenter(s) do not necessarily reflect the views and opinions of the Oncology Learning Network, HMP Global, or its employees and affiliates.
